All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?
Featured:
Tanya SiddiqiDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Tanya Siddiqi from City of Hope National Medical Center, Duarte, US, about the TRANSCEND CLL04 trial. Tanya Siddiqi specifically addresses whether the responses to JCAR017 are sustained in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).
Tanya Siddiqi discusses how over time 5 of 6 patients were in complete remission (CR) after six months, and stayed in CR after nine months, with three patients still in CR after 12 months. She mentions how this therapy could be an excellent option for patients who have relapsed multiple times from different therapies.
ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average time to secure a reimbursed CAR T-cell therapy manufacturing slot for patients with DLBCL (from decision to treatment with a CAR T-cell therapy)?